Search General Info
Search Education
Search Partnering Companies
![BIF](/sites/default/files/2023-05/230112-bio-bif-logo-color-horiz.jpg)
Stanford SPARK translational program
A nanoparticle antibiotic adjuvant that has the ability to target persister cells in biofilms of chronic bacterial infections and reverse the resistance of multi-resistant bacteria to commonly used antibiotics. Excellent in vitro and in vivo efficacy against multiple bacterial species and on going safety and toxicology show an excellent safety profile.
A nanoparticle antibiotic adjuvant that has the ability to target persister cells in biofilms of chronic bacterial infections and reverse the resistance of multi-resistant bacteria to commonly used antibiotics. Excellent in vitro and in vivo efficacy against multiple bacterial species and on going safety and toxicology show an excellent safety profile.
![](/sites/default/files/hubb_images/2996/attachments/%2520-%2520f1_Stanford_20University_dbf3a881.jpg)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2020
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Antibiotic adjuvant for chronic bacterial infections
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
![photo](/act-root/bio/assets/images/profile-default.png)
Biotechnology Innovation Organization
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved